Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

1372 - An open label randomized phase 2, study of weekly vs 3 weekly paclitaxel and carboplatin in stage IVB or recurrent carcinoma cervix


19 Dec 2015


Gynaecological cancers


Harish Pathalingappa


Annals of Oncology (2015) 26 (suppl_9): 80-84. 10.1093/annonc/mdv525


H. Pathalingappa, L. Kumar

Author affiliations

  • Medical Oncology, BRA -IRCH, All India Institute of Medical Sciences, 110029 - New Delhi/IN


Abstract 1372


To compare weekly and three weekly schedules of paclitaxel and carboplatin in stage IVB or recurrent or persistent carcinoma cervix.


This was a prospective, randomized phase II pilot study. Consecutive patients of metastatic, recurrent or persistent carcinoma cervix were enrolled in the study after taking informed consent and institutional ethics committee aproval. (IESC/T-352/38/2013RT23/1/11/2013). Eligible patients were: Histologically proven case of squamous or adeno or adenosquamous carcinoma, ECOG performance status (PS0) 0,1or 2, Measurable disease by CT scan. Patients with ECOG PS 3 or 4, impaired renal /liver functions, prior chemotherapy for metastatic disease, HIV positive, CNS metastasis, bilateral hydronephrosis were excluded. Patients were randomized by a random table into two arms. Arm 1 received paclitaxel 60 mg/ m2, carboplatin AUC 2 every weekly. Arm 2 received paclitaxel 175 mg/ m2, carboplatin AUC 6 every three weekly. Patients were followed up and responses were assessed after three cycles and every three monthly thereafter


Between September 2013 and January 2014, 52 patients were enrolled; four were considered ineligible, one declined chemotherapy, and three patients withdrew after 1st cycle of chemotherapy. 23 patients in each arm were eligible for assessment. Median age in both groups was 50 years. Three weekly chemotherapy was associated with better response rate (43% vs 13%), longer progression free survival (PFS) 7.6 (95% CI, 5.9-9.5) months vs 4.7 (95% CI 3.6-5.7) months, (p = 0.03). However, 1 year PFS was comparable (12.4% in three weekly vs 13% in weekly arm, p = 0.8). OS was higher in 3 weekly arm, 11.9 vs 7 months, HR 0.4, 95% CI 0.1- 0.9, p = 0.04. More patients (73% vs 48%) completed therapy in 3 weekly arm. More patients (86% vs 65%) required PRBC transfusion in weekly arm.


Three weekly paclitaxel and carboplatin can be used in the treatment of recurrent and metastatic cervical cancer. Three weekly schedule was associated with better response rates, improved PFS and OS compared to weekly schedule. Major toxicity associated with both regimens were myelosuppression. Anemia was higher in weekly arm.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings